awmsg logo



mecasermin (Increlex®)


Reference No. 196

Publication date:
06/11/2009


Appraisal information

mecasermin (Increlex®) 10 mg/ml solution for injection


Company: Ipsen Ltd
BNF category: Endocrine system
NMG meeting date: 16/09/2009
AWMSG meeting date: 14/10/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1709
Ministerial ratification: 03/11/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Mecasermin (Increlex®) is recommended for use within NHS Wales for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-I deficiency. Treatment should be initiated and monitored by physicians who are experienced in the diagnosis and management of patients with growth disorders. AWMSG is of the opinion that mecasermin (Increlex®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download